Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice

Table 2 Effect of pretreatment with rosiglitazone on serum alanine aminotransferase, tumor necrosis factor-α, IL-1β and IL-6 levels in rats after administration of lipopolysaccharide (n=6, mean ± SE)

	Sham + vehicle	BDL + vehicle	Sham + ROSI	BDL + ROSI
ALT (U/L)	78.6 ± 8.1	329.4 ± 40.5	42.3 ± 5.7a	303.0 ± 46.6
TNF-α (pg/mL)	770.5 ± 52.5	2017.9 ± 167.5	517.0 ± 69.7a	1984.0 ± 181.1
IL-1β (pg/mL)	1096.1 ± 101.7	2345.2 ± 194.7	648.4 ± 111.4a	2226.7 ± 209.8
IL-6 (pg/mL)	4479.4 ± 377.4	10774.4 ± 675.4	2758.5 ± 497.7a	9847.1 ± 865.1

^aP < 0.05 for vehicle (dimethyl sulfoxide) pretreatment vs rosiglitazone pretreatment group. BDL: Bile duct ligation; ROSI: Rosiglitazone; ALT: Alanine aminotransferase; TNF-α: Tumor necrosis factor-α.